Poster
9
(#9) Real-World Healthcare Resource Utilization and Costs Among US Individuals Living with Schizophrenia who Transitioned to Aripiprazole 2-Month Ready-To-Use Formulation
Psych Congress 2025
Abstract: Background
Nonadherence to oral antipsychotics (OAPs) in schizophrenia is common and contributes to increased healthcare resource utilization (HCRU) and costs. The long-acting injectable aripiprazole 2-Month Ready-To-Use (Ari 2MRTU) may improve adherence and reduce HCRU.
Objective
Characterize patient profiles, adherence, HCRU, and costs among individuals diagnosed with schizophrenia who transitioned from OAPs or aripiprazole once-monthly (AOM) to Ari 2MRTU based on a pre-post analysis.
Methods
This retrospective, non-interventional database study analyzed Kythera Labs closed claims (April 2022-March 2025) to identify commercial and Medicaid-insured US adults (≥18 years) with schizophrenia transitioning from OAPs or AOM to Ari 2MRTU (Ari 2MRTU transition date = index date). Patients were required to have continuous enrollment for 12 months pre- and 6 months post-index. Outcomes included adherence (proportion of days covered [PDC], medication possession ratio [MPR]), HCRU, and costs.
Results
Among patients who transitioned from OAPs to Ari 2MRTU (n=229), adherence improved post-index (PDC: 0.59 to 0.76, p.001; MPR: 0.66 to 0.87, p.001) versus 6 months pre-index. The proportion of patients with ≥1 schizophrenia-related outpatient visit declined (54.6% to 37.1%, p=.008). Total psychiatry-related medical (inpatient, outpatient, emergency) costs declined significantly in the post-index period ($584.44 to $208.36; p=0.02). Among patients transitioning from AOM to Ari 2MRTU (n=526), adherence significantly improved (PDC: 0.62 to 0.86, p.001; MPR: 0.67 to 0.92, p.001); all-cause length of stay decreased (1.05 to 0.64 days, p=.047).
Conclusion
Transition to Ari 2MRTU seems to improve adherence and reduce HCRU, supporting its potential as a treatment option in the management of schizophrenia.
Short Description: This study examined the pre post impact on adherence, health care resource utilization, and cost among patients living with schizophrenia who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral antipsychotic therapies or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H Lundbeck A/S
Nonadherence to oral antipsychotics (OAPs) in schizophrenia is common and contributes to increased healthcare resource utilization (HCRU) and costs. The long-acting injectable aripiprazole 2-Month Ready-To-Use (Ari 2MRTU) may improve adherence and reduce HCRU.
Objective
Characterize patient profiles, adherence, HCRU, and costs among individuals diagnosed with schizophrenia who transitioned from OAPs or aripiprazole once-monthly (AOM) to Ari 2MRTU based on a pre-post analysis.
Methods
This retrospective, non-interventional database study analyzed Kythera Labs closed claims (April 2022-March 2025) to identify commercial and Medicaid-insured US adults (≥18 years) with schizophrenia transitioning from OAPs or AOM to Ari 2MRTU (Ari 2MRTU transition date = index date). Patients were required to have continuous enrollment for 12 months pre- and 6 months post-index. Outcomes included adherence (proportion of days covered [PDC], medication possession ratio [MPR]), HCRU, and costs.
Results
Among patients who transitioned from OAPs to Ari 2MRTU (n=229), adherence improved post-index (PDC: 0.59 to 0.76, p.001; MPR: 0.66 to 0.87, p.001) versus 6 months pre-index. The proportion of patients with ≥1 schizophrenia-related outpatient visit declined (54.6% to 37.1%, p=.008). Total psychiatry-related medical (inpatient, outpatient, emergency) costs declined significantly in the post-index period ($584.44 to $208.36; p=0.02). Among patients transitioning from AOM to Ari 2MRTU (n=526), adherence significantly improved (PDC: 0.62 to 0.86, p.001; MPR: 0.67 to 0.92, p.001); all-cause length of stay decreased (1.05 to 0.64 days, p=.047).
Conclusion
Transition to Ari 2MRTU seems to improve adherence and reduce HCRU, supporting its potential as a treatment option in the management of schizophrenia.
Short Description: This study examined the pre post impact on adherence, health care resource utilization, and cost among patients living with schizophrenia who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral antipsychotic therapies or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H Lundbeck A/S
